TheDaoIndex KDAO2011
4 years 8 months ago
My patient measures morning stiffness in his joints by coffee units. Today, it’s 3 ☕️- an equivalent of 1 hour. #rheumatology
The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).
The GRA database of rheumatic patients also includes information about pregnancy; further obstetric details and outcomes were gathered from referring physicians.
Dr. John Cush RheumNow
4 years 8 months ago
In Mouse Model of Lupus, when the gut microbiome of NZM2410 mice colonized w/ SFB, glomerulonephritis worsened & was assoc. w/ incr in TH17, MCP-1 and CXCL1, & more microbial abundance & biodiversity (dysbiosis) https://t.co/bLxrJZKTDZ
Dr. John Cush RheumNow
4 years 8 months ago
NICE (UK) has recommended upadacitinib for use in active Psoriatic Arthritis, 15 mg qd +/- MTX, in pts not responding to DMARDS. UPA can now be used in England Wales and Scotland https://t.co/JFxMrgjrUe
Dr. John Cush RheumNow
4 years 8 months ago
The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027. https://t.co/hQTDc0ajdN
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: Comorbidities Drive Risk of Severe Outcomes with COVID-19
https://t.co/9GgfvgnMke https://t.co/JGHp0mVPpF
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/tc5D3Bwnnj
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: Cosentyx (secukinumab) was FDA approved for use in pediatric psoriatic arthritis & enthesitis-related arthritis, based on results of the ph III JUNIPERA study. Dosing based on weight (SEC 75 mg sc if 15-50kg; SEC 150 mg sc if 50 kg or more) https://t.co/S6mQmwKT1X
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children
Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents.
Read more : https://t.co/OAPdLCxHgy https://t.co/0RnYKeg891
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: New Onset Rheumatic Disorders with COVID-19 Infection
The journal Cells has published a review of new rheumatic disorders following COVID-19 infection.
Read more: https://t.co/X2DLznJynL https://t.co/wLCWt7gwgf
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: Infectious mimics of #RA include viruses (Parvo B19, HBV, HCV, HIV, Chikungunya alphaviruses) mycobacterial infections (Poncet's dz, TB, leprosy), bacterial arthritis, brucellosis and Lyme disease. https://t.co/3FOydnsj1V
Dr. John Cush RheumNow
4 years 8 months ago
In case you missed it…
Autoantibody Associations in Systemic Sclerosis
https://t.co/sOe4A8OzQp https://t.co/jjYBVH05Iy
Dr. John Cush RheumNow
4 years 8 months ago
Register for RheumNow Live, March 19-20, 2022.
You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office.
You can also receive CME credit!
https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c
